Phase I study of MRX34, a liposomal miR-34a mimic, administered twice weekly in patients with advanced solid tumors

Muhammad S. Beg, Andrew Brenner, Jasgit C. Sachdev, +6

Investigational New Drugs

Tumor BiologyMedicinePathologyAdvanced Solid TumorsExtracellular Microvesicles +6

Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria

Stephanie Green, Geoffrey R. Weiss

Investigational New Drugs

OncologyToxicity CriteriaCancer ManagementSouthwest Oncology GroupClinical Endpoint +6

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

Lawrence M. Gelbert, Shufen Cai, Xi Lin, +14

Investigational New Drugs

Phase II trial of gemcitabine (2,2′-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreas

Ephraim S. Casper, Mark R. Green, David P. Kelsen, +5

Investigational New Drugs

OncologyPhase Ii TrialPancreatic CancerMedicinePancreatic Surgery +3

Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme

Susan M. Chang, Patrick Y. Wen, Timothy F. Cloughesy, +13

Investigational New Drugs

Neuro-oncologyTumoral PathologyGliomaMedicineRecurrent Glioblastoma Multiforme +7

A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma

Jonathan E. Rosenberg, Richard Bambury, Eliezer M. Van Allen, +10

Investigational New Drugs

UrologyPhase Ii TrialGenitourinary CancerMedicineAnti-cancer Agent +3

Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer

Kenneth J. Pienta, Jean-Pascal Machiels, Dirk Schrijvers, +9

Investigational New Drugs

Cnto 888MedicineHuman Monoclonal AntibodyImmunologyImmune Checkpoint Inhibitor +6

Phase I/II study with ruthenium compound NAMI-A and gemcitabine in patients with non-small cell lung cancer after first line therapy

Suzanne Leijen, Sjaak A. Burgers, Paul Baas, +7

Investigational New Drugs

OncologyPhase I/ii StudyMedicineBronchial NeoplasmPharmacotherapy +8

A phase I and pharmacokinetic study of silybin-phytosome in prostate cancer patients

Thomas W. Flaig, Daniel L. Gustafson, Lih‐Jen Su, +6

Investigational New Drugs

UrologyOncologyMedicineProstate Cancer PatientsPharmacokinetic Study +4

A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma

Evan M. Hersh, Steven O’Day, John D. Powderly, +7

Investigational New Drugs

Chemotherapy-naïve PatientsMedicineMelanomaPharmacologyImmune Checkpoint Inhibitor +5